Paratek Pharmaceuticals (PRTK) Earning Somewhat Favorable Media Coverage, Analysis Shows
Headlines about Paratek Pharmaceuticals (NASDAQ:PRTK) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 45.4116308596051 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several brokerages have recently commented on PRTK. Guggenheim assumed coverage on Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They set a “buy” rating and a $44.00 target price for the company. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 17th. Zacks Investment Research lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. BidaskClub lowered Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd. Finally, Raymond James Financial restated a “strong-buy” rating and set a $36.00 target price on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Paratek Pharmaceuticals currently has an average rating of “Buy” and an average target price of $40.00.
Paratek Pharmaceuticals (NASDAQ PRTK) traded down $0.15 during midday trading on Wednesday, reaching $17.50. The company’s stock had a trading volume of 571,900 shares, compared to its average volume of 574,636. Paratek Pharmaceuticals has a twelve month low of $13.15 and a twelve month high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.